Globus Medical (GMED) CFO sells 18,542 shares after option exercises

Rhea-AI Filing Summary

Globus Medical reported insider activity by its Senior Vice President and Chief Financial Officer. On December 1, 2025, the executive exercised multiple stock options for Class A common stock, acquiring 3,646 shares at $53.14, 5,000 shares at $56.43, 5,000 shares at $64.44, and 4,896 shares at $63.68. The same day, the executive sold 18,542 shares at $90 per share, leaving no directly held Class A common stock after the reported transactions.

The filing notes that the sale was carried out under a Rule 10b5-1 trading plan dated August 25, 2025. The options exercised were previously granted awards that vest over four years or are already fully vested, with expiration dates ranging from 2031 to 2034.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kline Kyle

(Last) (First) (Middle)

VALLEY FORGE BUSINESS CENTER

2560 GENERAL ARMISTEAD AVENUE

(Street)

AUDUBON PA 19403

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GLOBUS MEDICAL INC [ GMED ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior Vice President, CFO

3. Date of Earliest Transaction (Month/Day/Year)
12/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	12/01/2025		M		3,646	A	$53.14	3,646	D
Class A Common Stock	12/01/2025		M		5,000	A	$56.43	8,646	D
Class A Common Stock	12/01/2025		M		5,000	A	$64.44	13,646	D
Class A Common Stock	12/01/2025		M		4,896	A	$63.68	18,542	D
Class A Common Stock	12/01/2025		S(1)		18,542	D	$90	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy Class A Common Stock)	$53.14	12/01/2025		M			3,646	(2)	03/24/2033	Class A Common Stock	3,646	$0	1,354	D
Stock Option (Right to Buy Class A Common Stock)	$56.43	12/01/2025		M			5,000	(3)	02/27/2034	Class A Common Stock	5,000	$0	10,000	D
Stock Option (Right to Buy Class A Common Stock)	$64.44	12/01/2025		M			5,000	(4)	01/25/2031	Class A Common Stock	5,000	$0	0	D
Stock Option (Right to Buy Class A Common Stock)	$63.68	12/01/2025		M			5,000	(5)	01/27/2032	Class A Common Stock	5,000	$0	0	D

Explanation of Responses:

1. This sale was effectuated pursuant to a Rule 10b5-1 trading plan dated August 25, 2025 executed by the reporting person.

2. These options were granted on March 24, 2023, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2024, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.

3. These options were granted on February 27, 2024, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2025, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.

4. These options were granted on January 25, 2021 and are fully vested.

5. These options were granted on January 27, 2022, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2023, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.

	/s/ Kelly G. Huller, Attorney-in-Fact	12/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Globus Medical (GMED) disclose in this Form 4?

The Senior Vice President and CFO of Globus Medical reported exercising several stock options for Class A common stock and selling 18,542 shares at $90 per share on December 1, 2025.

How many Globus Medical (GMED) shares did the CFO own after the reported transactions?

Following the reported transactions on December 1, 2025, the CFO directly held 0 shares of Globus Medical Class A common stock, as shown in the filing.

Were the Globus Medical (GMED) insider sales made under a Rule 10b5-1 trading plan?

Yes. The filing states that the 18,542-share sale was effectuated pursuant to a Rule 10b5-1 trading plan dated August 25, 2025, executed by the reporting person.

What stock options did the Globus Medical (GMED) CFO exercise in this Form 4?

The CFO exercised stock options to acquire 3,646 shares at $53.14, 5,000 shares at $56.43, 5,000 shares at $64.44, and 4,896 shares at $63.68 of Class A common stock on December 1, 2025.

What are the vesting terms of the Globus Medical (GMED) options referenced in the filing?

Options granted on March 24, 2023 and February 27, 2024 vest over four years, with one-fourth vesting on January 1 of the year following the vesting commencement date and the remainder vesting monthly over the next 36 months. Options granted on January 25, 2021 are fully vested, and those granted on January 27, 2022 vest over a similar four-year schedule.

Does the Globus Medical (GMED) CFO still hold stock options after these transactions?

Yes. After the reported transactions, the filing shows remaining stock options, including 1,354 options with a $53.14 exercise price and 10,000 options with a $56.43 exercise price, with expiration dates in 2033 and 2034, respectively.